Frank R. Wellborne

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

William Stohl, Falk Hiepe, Kevin Latinis et al. · Arthritis & Rheumatism · 2012 · 416 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

Philip J. Mease, P A Ory, John T. Sharp et al. · Annals of the Rheumatic Diseases · 2008 · 267 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Clinical Assessment of Pain, Tolerability, and Preference of an Autoinjection Pen Versus a Prefilled Syringe for Patient Self-Administration of the Fully Human, Monoclonal Antibody Adalimumab: The TOUCH Trial

Alan Kivitz, Steven M. Cohen, James E. Dowd et al. · Clinical Therapeutics · 2006 · 136 citations

Pharmacy, Immunology, Pharmacotherapy +17

Long‐term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus

Joan T. Merrill, Ellen M. Ginzler, Daniel J. Wallace et al. · Arthritis & Rheumatism · 2012 · 117 citations

Medicine, Clinical Sciences, Pharmacotherapy +11

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies

Ara Dikranian, Miguel Á. González‐Gay, Frank R. Wellborne et al. · RMD Open · 2022 · 29 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15